Robert Alexander - ZS Pharma Insider

CEO and Director

Dr. Robert Alexander. Ph.D . is the Chief Executive Officer Director of ZS Pharma Inc. He has served as a member of our board of directors since October 2012 and has served as our Chief Executive Officer since December 2013. From March 2013 to March 2014 Dr. Alexander served as Chairman of our board of directors. From November 2005 to March 2013 Dr. Alexander served as a Director at Alta Partners a VC firm in life sciences. In addition he acted as Executive Chairman and interim Chief Executive Officer of SARcode Biosciences a biopharmaceutical company. During his time at Alta he led investments in SARcode Biosciences Sonexa Therapeutics Allakos Lumena Pharmaceuticals and ZS Pharma. From April 2004 to November 2005 Dr. Alexander was a Principal in MPM Capitals BioEquities fund where he sourced opportunities and led due diligence efforts for both public and private investments. From December 2000 to April 2004 Dr. Alexander worked in the Business Development group at Genentech Inc. a biotechnology company where he was responsible for sourcing and screening product opportunities based on scientific merit and strategic fit leading diligence teams and negotiating terms and definitive agreements
Age: 44  CEO Since 2014  Ph.D    
650-458-4100  http://www.zspharma.com
Alexander joined Genentech after completing his postdoctoral fellowship at Stanford University in the Pathology department. He also holds a Ph.D. in Immunology from the University of North Carolina and a B.A. in Zoology from Miami University of Ohio. We believe Dr. Alexander is qualified to serve on our board of directors based on his background and experience in the life sciences sector.

Management Efficiency

The company has return on total asset (ROA) of (0.99) % which means that it has lost $0.99 on every $100 spent on asset. This is way below average.
The company currently holds 10.39 M in liabilities with Debt to Equity (D/E) ratio of 0.05 which may suggest the company is not taking enough advantage from borrowing. ZS Pharma Inc has Current Ratio of 10.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

ZS Pharma, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of nonabsorbed drugs to treat renal, cardiovascular, liver, and metabolic diseases. ZS Pharma Inc (ZSPH) is traded on NASDAQ General Markets in USA. It is located in TEXAS, U.S.A and employs 184 people. ZS Pharma is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Equity Analysis Now
   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Hide  View All  Next  Launch Equity Analysis
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add ZS Pharma Inc to your portfolio

Top Management

ZS Pharma Inc Leadership Team
Jeffrey Farrow, CFO
D Keyser, Director
Srinivas Akkaraju, Director, Ph.D
John Whiting, Director, MBA
Adam Tomasi, Executive, MBA
Robert Alexander, CEO, Ph.D
Marc Ostro, Director, Ph.D
Martin Babler, Director
Guy Nohra, Director, MBA
Alvaro Guillem, Founder, Ph.D
Jeffrey Keyser, COO
Cynthia Smith, Executive, MBA
Mark Asbury, President
Henrik Rasmussen, Executive, Ph.D
Kimberly Popovits, Director

Stock Performance

ZS Pharma Performance Indicators